A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Phase 1 Completed 23 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupOpen-labelPrevention

Summary

Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies

Timeline

Start: 2013-06-28
Primary completion: 2018-08-21
Completion: 2018-08-21

Publications

Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, Socie G, Medinger M, Passweg J, Teshima T, Stylianou C, Oehen S, Heim D, Bucher C. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy. Transplant Cell Ther. 2023 Jan;29(1):41.e1-41.e9. doi: 10.1016/j.jtct.2022.10.029. Epub 2022 Nov 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Study Part 1: KRP203	Unknown	1 mg	—
Subject	Study Part 1: KRP203	Unknown	3 mg	—

A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Summary

Timeline

Publications

Drugs

Indications